Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
| dc.authorid | Bilici, Ahmet/0000-0002-3192-456X | |
| dc.authorid | Aksoy, Sercan/0000-0003-4984-1049 | |
| dc.authorid | Öksüzoğlu Çakmak, Ömür Berna/0000-0002-2756-8646 | |
| dc.authorwosid | Bilici, Ahmet/E-2062-2018 | |
| dc.authorwosid | Sendur, Mehmet Ali Nahit/H-7555-2014 | |
| dc.authorwosid | Aksoy, Sercan/S-2480-2019 | |
| dc.authorwosid | Arslan, Cagatay/I-1932-2016 | |
| dc.authorwosid | Gumus, Mahmut/HTO-4176-2023 | |
| dc.authorwosid | Öksüzoğlu Çakmak, Ömür Berna/HKN-6428-2023 | |
| dc.contributor.author | Bilici, Ahmet | |
| dc.contributor.author | Olmez, Omer Fatih | |
| dc.contributor.author | Sezer, Ahmet | |
| dc.contributor.author | Oksuzoglu, Berna | |
| dc.contributor.author | Kaplan, Muhammet Ali | |
| dc.contributor.author | Karadurmus, Nuri | |
| dc.contributor.author | Cubukcu, Erdem | |
| dc.date.accessioned | 2024-08-04T21:00:58Z | |
| dc.date.available | 2024-08-04T21:00:58Z | |
| dc.date.issued | 2022 | |
| dc.department | İnönü Üniversitesi | en_US |
| dc.description | Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORK | en_US |
| dc.description.abstract | [Abstract Not Available] | en_US |
| dc.description.sponsorship | Amer Soc Clin Oncol | en_US |
| dc.description.sponsorship | Roche Pharmaceuticals | en_US |
| dc.description.sponsorship | Roche Pharmaceuticals. | en_US |
| dc.identifier.issn | 0732-183X | |
| dc.identifier.issn | 1527-7755 | |
| dc.identifier.issue | 16 | en_US |
| dc.identifier.uri | https://hdl.handle.net/11616/103982 | |
| dc.identifier.volume | 40 | en_US |
| dc.identifier.wos | WOS:000863680302513 | en_US |
| dc.identifier.wosquality | Q1 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Lippincott Williams & Wilkins | en_US |
| dc.relation.ispartof | Journal of Clinical Oncology | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | [No Keywords] | en_US |
| dc.title | Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study). | en_US |
| dc.type | Conference Object | en_US |
